FDA Panel Backs Liraglutide to Reduce CV Risk Factors FDA Panel Backs Liraglutide to Reduce CV Risk Factors

An FDA panel recommended liraglutide for the additional indication of reducing the risk for major adverse cardiovascular events in adults with type 2 diabetes mellitus and high cardiovascular risk.Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news